medicare glp-1 coverage Recent Trends in Use and Spending in 🚨 BIG NEWS FOR MEDICARE

Description

(The Washington Post notes that some Part D plans do cover Wegovy if prescribed for reducing cardiovascular risk, or Zepbound for obstructive sleep apnea, but not for obesity ( [38] ) ( [39] ).) In summary, nearly all current GLP-1 weight-loss usage depends on commercial/employer coverage , which is highly variable and restrictive

The semaglutide versus tirzepatide comparison shows tirzepatide achieving 20-22.5% body weight reduction at the highest dose versus 14.9% for semaglutide

R., Tschop, M

Modelling of treatment response We aimed to build models of treatment response that combined both genetic and non-genetic predictors

On Scotts point about the expense of US healthcare versus its effectiveness as compared to the G7 he seems to have missed the elephant in the room the US healthcare system